摘要
目的:重点研究和探讨爱通立(阿替普酶)急诊静脉溶栓治疗急性心肌梗死患者的临床疗效及安全性。方法:利用回顾性分析的方法研究和比较对本院于2011年1月-2012年12月收治的30例急性心肌梗死患者的临床资料。将30例患者随机分成治疗组15例和对照组15例,治疗组采用爱通立(阿替普酶)急诊静脉溶栓进行治疗,对照组采用尿激酶急诊静脉溶栓进行治疗。比较两组患者的冠状动脉再通率和溶栓并发症发生情况。结果:治疗组治疗后的冠脉再通率比对照组低,治疗组患者治疗后的冠脉再通率为80.00%,对照组患者治疗后的冠脉再通率为73.33%,治疗组患者治疗后的溶栓并发症发生率比对照组低,两组间差异具有统计学意义(P<0.05)。结论:爱通立(阿替普酶)急诊静脉溶栓治疗急性心肌梗死具有很好的临床疗效,并且具有良好的安全性。
Objective：To focus on and discuss love Tongli（alteplase）clinical efficacy and safety of intravenous thrombolysis in patients with acute myocardial infarction.Method：Used retrospective study method to analyse and compare our hospital in 2011 January -2012 year in December 30 cases of patients with acute myocardial infarction. 30 patients were randomly divided into the treatment group of 15 cases and 15 cases in the control group,treatment group was given love Tongli（alteplase）emergency intravenous thrombolytic therapy,the control group was given urokinase intravenous thrombolysis in emergency treatment. And compared the 2 groups of patients with coronary artery recanalization rate of thrombolysis and complications. Result：The recanalization rate was lower than the control group in treatment of coronary artery in patients after treatment,treatment of coronary artery in the patients with recanalization rate was 80.00%,control group patients after coronary artery recanalization rate was 73.33%,complications of thrombolytic therapy group were lower than those in the control group the incidence of. Differences between the two groups was significant,there was statistical significance（P ＆lt;0.05）.Conclusion：Love Tongli（alteplase）emergency intravenous thrombolytic therapy has good clinical efficacy in treatment of acute myocardial infarction,and has good security.
出处
《中国医学创新》
CAS
2013年第19期38-39,共2页
Medical Innovation of China
关键词
爱通立
阿替普酶
静脉溶栓
急性心肌梗死
Love Tongli
Alteplase
Intravenous thrombolysis
Acute myocardial infarction
